Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Health

Ananda Developments explains what a PK study is and why it's important

Ananda Developments PLC (AQSE:ANA) recently hired a contract research specialist in Australia to glean key insights on potential chronic pain treatment, MRX1. This evaluation, known as a pharmacokinetic (PK) study, aims to understand how MRX1 moves through the body—how it's absorbed, distributed, metabolised, and eventually excreted. The results will help researchers determine the safest and most effective dose for patients. PK studies are crucial in developing new medicines as they guide dosing decisions and ensure safety. To learn more, check out our detailed explainer [here].

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK